Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 8 days ago

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery

Bristol-Myers Squibb Company (NYSE:BMY) is one of the most undervalued stocks to buy and hold for 5 years. On October 1, Bristol-Myers Squibb, Takeda Pharmaceuticals (NYSE:TAK), and Astex Pharmaceuticals agreed to collaborate and pool prop... Full story

Yahoo Finance • 11 days ago

Volatus Aerospace et VoltaXplore signent une lettre d’intention pour l’approvisionnement en batteries canadiennes destinées aux drones de prochaine génération

MONTRÉAL, 30 sept. 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV : FLT) (OTCQB : TAKOF) (FSE : ABB.F), un chef de file canadien dans le domaine de l’intelligence aérienne et des systèmes d’aéronefs sans pilote, et VoltaXplore Inc... Full story

Yahoo Finance • 15 days ago

Trump’s 100% drug tariffs send pharma stocks lower

[Many different pills on pink background. Prescription pills and vitamins. Flat lay and space for text.] Baurzhan Ibrashev European and Asian pharmaceutical stocks fell Friday after President Donald Trump unveiled sweeping new tariffs, in... Full story

Yahoo Finance • 18 days ago

Volatus Aérospatial étend la commande de drones ISR de l'OTAN à 1,7 million $ et commence les livraisons

TORONTO, 23 sept. 2025 (GLOBE NEWSWIRE) -- Volatus Aérospatial Inc. (TSXV : FLT) (OTCQX : TAKOF) (Francfort : ABB), un chef de file canadien dans le renseignement aérien et les solutions de fret, est heureux d'annoncer que le contrat de... Full story

Yahoo Finance • 25 days ago

Volatus Aerospace Secures Major Multi-Year Agreement with a Leading North American Power Utility to Provide Drone-Based Services

TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQB: TAKOF) (FSE: ABB.F) (“Volatus” or the “Company”), is pleased to announce that it has entered into a multi-year agreement with one of North America’s l... Full story

Yahoo Finance • 27 days ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 30 days ago

Takeda names Lilly's Rhonda Pacheco as President of the U.S. unit

[Business person working in office] maroke/iStock via Getty Images Takeda (NYSE:TAK [https://seekingalpha.com/symbol/TAK]) said on Thursday that Rhonda Pacheco, who was the group vice president of U.S. cardiometabolic health at Eli Lilly... Full story

Yahoo Finance • last month

Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment

GAITHERSBURG, Md., Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by regulatory approval for Novavax's COVID-19 vaccine Nuvaxovid® Intramuscular Injection 1 mL... Full story

Yahoo Finance • last month

FVD's Underlying Holdings Could Mean 10% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • last month

Takeda's Fruzaqla Publicly Reimbursed In Quebec For Treatment Of Metastatic Colorectal Cancer

(RTTNews) - Takeda Canada Inc. Thursday announced that Fruzaqlatm (fruquintinib capsules) will now be reimbursed by Régie de l'assurance maladie for people in Quebec, under certain criteria, as a treatment for adult patients with metastati... Full story

Yahoo Finance • 2 months ago

Carbon Offsets Offset Market Transforms Amidst Quality Control Measures and Price Restructuring

Dublin, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Carbon Offsets" report has been added to ResearchAndMarkets.com's offering. Carbon offsets are tradable certificates representing one tonne of carbon dioxide (CO?... Full story

Yahoo Finance • 2 months ago

Dementia Treatment Market Size to Surpass USD 33.54 Billion by 2032, Fueled by Breakthrough Therapies and Growing Patient Awareness – SNS Insider

Austin, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Dementia Treatment Market Size & Growth Outlook According to SNS Insider, the global Dementia Treatment Market was valued at USD 17.06 billion in 2023 and is projected to reach USD 33.54 billion... Full story

Yahoo Finance • 2 months ago

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

Company Logo The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies lik... Full story

Yahoo Finance • 2 months ago

United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering. United States Epilepsy Drugs Market is expec... Full story

Yahoo Finance • 2 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path for Sanfilippo syndrome Type A aligned... Full story

Yahoo Finance • 2 months ago

Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035

Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy Market - A Global and Regional Analysis: Focus on Distribution Channel, Route of Administration, and Region - Analysis and Forecast, 2025-20... Full story

Yahoo Finance • 2 months ago

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year in... Full story

Yahoo Finance • 2 months ago

TAK Crosses Below Key Moving Average Level

In trading on Wednesday, shares of Takeda Pharmaceutical Co Ltd (Symbol: TAK) crossed below their 200 day moving average of $14.23, changing hands as low as $13.95 per share. Takeda Pharmaceutical Co Ltd shares are currently trading off a... Full story

Yahoo Finance • 2 months ago

Takeda Pharmaceutical Non-GAAP EPS of ¥151.00, revenue of ¥1106.7B; reaffirms FY outlook

* Takeda Pharmaceutical press release [https://seekingalpha.com/pr/20182127-takeda-announces-first-quarter-fy2025-results-with-significant-late-stage-pipeline] (NYSE:TAK [https://seekingalpha.com/symbol/TAK]): Q1 Non-GAAP EPS of ¥151.00.... Full story

Yahoo Finance • 2 months ago

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline atActual Exchange Rates (AER) as VYVANSE®Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit Decline of 11.9% at CER, Primarily Refle... Full story